Prospective clinical research on safety and efficacy of TAPCOM Combination Ophthalmic Solution switched from Xalatan Ophthalmic Solution

Prospective clinical research on safety and efficacy of TAPCOM Combination Ophthalmic Solution switched from Xalatan Ophthalmic Solution - Prospective clinical research on safety and efficacy of TAPCOM Combination Ophthalmic Solution switched from Xalatan Ophthalmic Solution

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016465

Enrollment

Registered

2015-02-06

Start date

2014-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open angle glaucoma or ocular hypertension

Interventions

switch Xalatan Ophthalmic Solution to TAPCOM Combination Ophthalmic Solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients whose IOP control with the monotherapy of Xalatan is considered insufficient by the investigator and patients with primary open angle glaucoma or ocular hypertension Patients who can submit informed consent in writing and visit the hospital according to the observation/test schedule determined in the study protocol

Exclusion criteria

Exclusion criteria: Patients with allergy to the ingredients used in the present study Patients who are contraindicated to Beta blockers Patients who the investigator consider ineligible for enrollment

Design outcomes

Primary

Measure	Time frame
Reduction of intraocular pressure Topical and systemic adverse event	—

Countries

Japan

Contacts

Public ContactHideaki Okumichi

Hiroshima University Hospital Ophthalmology

okumic@hiroshima-u.ac.jp082-257-5247

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026